VytronUS

About VytronUS

VytronUS, Inc. operated as a medical device company focused on developing treatments for cardiac arrhythmias, with a specific emphasis on atrial fibrillation (AFib).

The company was founded in 2006, establishing its headquarters in Sunnyvale, California. Over its operational history, VytronUS secured significant investment to fund its research and clinical trials, raising a total of $115 million across seven funding rounds. A notable financing event was a $49 million Series C round in July 2016, which included investors such as New Enterprise Associates, Apple Tree Partners, and BioStar Ventures, aimed at supporting technology refinements and clinical trials in the EU and US. Another key round was a $31.6 million Series B in October 2014. The company was led by President and CEO John Pavlidis, who joined in early 2015. Pavlidis brought extensive experience from the medical device sector, having previously served as CEO at Endoscopic Technologies (acquired by AtriCure) and R2 Technology (acquired by Hologic), and as President of the Ultrasound group at Siemens Healthcare. Tracxn lists the company as deadpooled, but no information regarding an acquisition or official closure has been found.

VytronUS's core business was the development of a proprietary cardiac imaging and ablation system for electrophysiologists. The technology, known as Low-Intensity Collimated Ultrasound (LICU), was engineered to provide a combined solution for both mapping and treating heart tissue. The system utilized a catheter-based platform that could generate high-resolution, 3D anatomical images of the heart's interior without direct tissue contact. This imaging capability allowed physicians to plan procedures by drawing a desired treatment pattern on a workstation. Subsequently, the same robotic-assisted catheter delivered the focused ultrasound energy to create continuous, linear lesions intended to block the abnormal electrical signals that cause arrhythmias. A primary benefit of the LICU system was its potential to automate the procedure, thereby reducing dependence on operator skill and increasing precision.